Needham & Company Reiterates a 'Buy' on CONMED (CNMD); Setting Positive Tone for 2012

Needham & Company reiterates a 'Buy' on CONMED (NASDAQ: CNMD) price target raised from $32 to $35.

Analyst, Dalton Chandler, said, "It continues to be slow going in the orthopedics market, weighed down in part by high unemployment and a poor economy, but CNMD exceeded expectations and management painted an optimistic picture for 2012. Between organic growth and the recently announced marketing deal with the Musculoskeletal Transplant Foundation our estimates are increasing substantially so we are raising our price target."

Needham boosts FY12 EPS estimate from $1.64 to $1.79.

For an analyst ratings summary and ratings history on CONMED click here. For more ratings news on CONMED click here.

Shares of CONMED closed at $29.81 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy